

88517_Auto_Edited.docx

Retrospective Study

Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Treatment of Hepatocellular Carcinoma with PVTT

Hongxiao Wu, Xiaoyan Ding, Yawen Xu, Minghua Yu, Xiaomi Li, Na Deng, Jinglong Chen

Abstract**BACKGROUND**

Hepatocellular carcinoma (HCC) patients complicated with portal vein tumor thrombus (PVTT) exhibit poor prognoses and treatment responses.

AIM

Our major aim was to critically evaluate the efficacies and safety levels of the combination of programmed cell death-1 (PD-1) inhibitor, transcatheter arterial chemoembolization (TACE), and Lenvatinib (the PTL regimen) in a completely dedicated cohort of HCC subjects comorbid with PVTT.

METHODS

From January 2019 to December 2020, HCC patients with PVTT types I-IV were retrospectively enrolled at Beijing Ditan Hospital. They were distributed to either the PTL or TL group. The median progression-free survival (mPFS) was set as the primary endpoint, while parameters like median overall survival (mOS), objective response rate (ORR), disease control rate (DCR), and toxicity level served as secondary endpoints.

RESULTS

Forty-one eligible patients were finally recruited for this study and divided into the PTL ($n = 18$) and TL ($n = 23$) groups. For a median follow-up of 21.8 months, the DCRs were 88.9% and 60.9% in the PTL and TL groups ($P = 0.046$), respectively. Moreover, mPFS indicated significant improvement ($HR=0.25$; $P<0.001$) in PTL-treated patients (5.4 months) compared to TL-treated (2.7 months) patients. There were no treatment-related deaths or differences in AEs in either group.

CONCLUSION

A triplet regimen of PTL was safe and well-tolerated as well as exhibited favorable efficacy over the TL regimen for advanced-stage HCC patients with PVTT types I-IV.

Key Words: Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Lenvatinib; PD-1 inhibitor; Portal vein tumor thrombus.

Wu H, Ding X, Xu Y, Yu M, Li X, Deng N, Chen J. Transcatheter Arterial Chemoembolization Combined with PD-1 Inhibitors and Lenvatinib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. *World J Gastroenterol* 2023; In press

Core Tip: HCC with PVTT has a poor prognosis and treatment responses. Assessment of its survival has important clinical implications. Through our research, we discovered that a triplet regimen of PTL was safe and well-tolerated as well as exhibited favorable efficacy over the TL regimen for advanced-stage HCC comorbid with PVTT.

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed primary malignancies of the liver that leads to high morbidity and mortality rates in adults, especially those with chronic liver diseases and hepatitis infections. In 2020, HCC

ranked sixth among all cancers concerning 4.7% of all new cancer cases, and third for 8.3% of all cancer-related deaths [1]. The portal vein tumor thrombus (PVTT) is a commonly occurring complication in at least 16-30% of HCC patients [2], contributes to poor prognosis, and increases the susceptibility to cancer recurrence, with the median survival of about 2.7-4 months without any interventions [3]. Although both EASL and AASLD guidelines suggested that HCC patients complicated with PVTT should be classified as BCLC-C stage and receive systemic treatments [4,5]. However, there is currently no optimal treatment strategy for such patients. Tyrosine kinase and immune checkpoint inhibitors (TKI and ICI, respectively) are generally applied in systemic therapies of HCC, while the combination of transcatheter arterial chemoembolization (TACE) with systemic therapeutics has substantially improved treatment outcomes in advanced-stage patients.

TACE is recommended for treating unresectable HCC [6-8], and its safety and effectiveness have been demonstrated in several clinical trials [9-12]. Despite this, in clinical practices, tumor recurrence and distant metastasis are often encountered in post-TACE HCC patients [13]. Several studies have confirmed better treatment responses when TACE is combined with TKI over TACE alone [14-16]. In the era of rapidly advancing immunotherapy research, studies suggest that ICI and TKI together can promote the recovery of cytotoxic T lymphocytes (CTLs) from exhaustion [17], thereby enhancing antitumor responses [18,19]. Retrospective studies suggest that a triplet regimen of TACE or a combination of hepatic arterial infusion chemotherapy (HAIC), Lenvatinib, and PD-1 inhibitor could be superior to dual therapy in advanced HCC cases [20-22]. However, there is limited data on highly complicated HCC patients, and the success rate of Atezolizumab plus Bevacizumab therapy has not yet been established for this subset of HCC patients [23]. Therefore, we hypothesized that the triplet regimen of TACE plus targeted drugs and ICIs might introduce better prognoses for HCC patients with PVTT. Here, we aimed to compare the safety and efficacy of the triplet regimen of Lenvatinib, PD-1 inhibitor, and TACE *vs* Lenvatinib plus TACE in advanced-stage HCC with type I-IV PVTT.

MATERIALS AND METHODS

Patient selection

Eligible patients were retrospectively enrolled at Beijing Ditan Hospital affiliated with Capital Medical University, between January 2019 and December 2020. Participants were distributed into two treatment groups - the PD-1 inhibitor/TACE/Lenvatinib (PTL) and TACE/Lenvatinib (TL) groups. HCC patients had different stages of PVTT without obstructing the major vein lumen or inferior vena cava. The Chinese Society of Clinical Oncology (CSCO) guidelines for liver carcinoma were followed to confirm the histological and clinical diagnoses of HCC [24]. The diagnosis of PVTT was confirmed either by radiological (e.g., CT and MRI) or pathological methods. As per Cheng's classification, the PVTT could be staged in four types. Type I tumor thrombus involves portal vein branches in segments; type II includes left and right branches of the hepatic portal vein; type III involves the main portal vein, and type IV affects the superior mesenteric vein or inferior vena cava [25].

The inclusion criteria comprised the following: 1) ages ranged from 18 to 75 years; 2) life expectancy ≥ 3 months; 3) having at least one typical enhanced measurable target lesion of ≥ 1 cm, according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST); 4) Eastern Cooperative Oncology Group-performance status (ECOG-PS) score 0-1; 5) Child-Pugh classification A or B (≤ 7 points); 6) non-surgical indications or refusal of surgical treatment; 7) not receiving radiofrequency ablation, TACE, and any other locoregional treatments 4 wk before the admission; 8) no limit on several liver tumors, and 9) might or might not have extrahepatic metastasis. The exclusion criteria included: 1) a history of other cancers; 2) any contraindications for therapies with TACE, Lenvatinib, and/or PD-1 inhibitor; 3) simultaneous ongoing treatment with other drugs; 4) incomplete patient record data, and 5) other conditions considered unsuitable for inclusion in the study by the investigators. Additionally, patients treated with any locoregional therapies (e.g., radiofrequency ablation and radiotherapy) for intrahepatic lesions of HCC 4 wk before the study enrollment were eliminated.

Treatments

TACE

TACE was carried out by 2 professional radiologists (C.L. and J.G.). First, the feeding artery of the tumor was determined by angiography, then a super-selective 5-F catheter was inserted. Then, a mixture of Lipiodol (5-20 mL; Lipiodol Ultra-Fluide; André Guerbet Laboratories) and Lobaplatin (20mg/m²; Changan Hainan International Pharmaceutical Co., China) was prepared for embolization using absorbable embospheres (300-500mm; Biosphere Medical Inc). ⁸ The entire intrahepatic tumor burden was treated by TACE. Conventional TACE (cTACE) was repeated on demand if the patient's subsequent follow-ups revealed incomplete necrosis or insufficient Lipiodol uptake.

Systemic therapy

Patients with ≥60kg and <60kg (or Child-Pugh class B) of body weights, respectively, received 12mg and 8mg of Lenvatinib orally once daily until the day of cTACE. In the absence of any post-TACE symptoms (fever, nausea, vomiting, *etc.*), the medication was resumed after each TACE treatment. Patients in the PTL group received intravenous doses of 200mg of PD-1 inhibitor (Sintilimab, Camrelizumab, Nivolumab, or Tislelizumab), every 3 wk starting from one to two weeks after TACE. When participants experienced adverse events (AEs) of grade 3 or more, dose modification or temporary interruption of medication was performed, according to the drug labels, until AEs were relieved to grade 1 or none. The drug was discontinued in case of uncontrolled tumor progression or unacceptable AEs.

Follow-up Visits

Post-TACE assessments were performed by chest, abdominal, or enhanced CT, MRI, and/or laboratory tests during the follow-up visits every 4-8 wk intervals. Laboratory tests included blood routine, hepatic and kidney function tests, quantitation of urine protein, serum α -fetoprotein (AFP), and myocardial enzymes, *etc.* AEs records were retrieved for analysis from the hospital's electronic record system, following the Common Terminology Criteria for Adverse Events (CTCAE, v5.0) guidelines. Transient

post-TACE AEs, such as elevated liver enzymes, abdominal discomforts, and fever, were not recorded. The end-point of the follow-up study was December 1st, 2021.

Endpoints

According to mRECIST criteria, median progression-free survival (mPFS) was the primary endpoint, while secondary endpoints included median overall survival (mOS), objective response rate (ORR), disease control rate (DCR), and safety. The mPFS was defined as the duration from the first TACE intervention to the first tumor progression and all-cause death. The mOS was the time from the first TACE to all-cause death. The ORR was the percentage of participants with complete remission (CR) and partial remission (PR). The DCR was referred to as the sum of CR, PR, and stable disease (SD). Tumor progression (20% increase from baseline examination, mRECIST) and transient hepatic dysfunction to Child-Pugh C or emerging extrahepatic metastases were conceived as markers of disease progression [26].

Statistical Analysis

Continuous data are presented as median \pm interquartile range (IQR) or mean \pm standard deviation (SD). The baseline characteristics of the two groups were evaluated by independent samples *t*-test or chi-squared (χ^2) test. The Kaplan-Meier and log-rank tests were employed to estimate survival curves and corresponding *P* values. Based on the Cox regression models, multivariate and univariate analyses were performed to identify independent prognostic factors related to mPFS. Any survival-related variables with *P*<0.10 from univariate analyses were combined into a multivariate Cox proportional hazards model. A two-tailed *P*-value of <0.05 was considered statistically significant. The SPSS v22.0 (IBM, Inc., New York) was exploited for all analyses.

RESULTS

Patient demographics

A total of 502 HCC cum PVTT cases were diagnosed in Beijing Ditan Hospital, of which 424 patients were not treated with Lenvatinib, 22 subjects were not treated with TACE, and 15 patients had incomplete follow-up data. Finally, 41 of these patients were

enrolled in the study, of which 23 were allotted to the TL group and the rest ($n = 18$) patients to the PTL group (Figure 1). The baseline data of 41 patients are outlined in Table 1. The median age of the patients was 57.6 ± 8.8 years. Thirty-six percent ($n = 15$) of patients in both groups had extrahepatic metastases, and most patients presented PVTT types IIHV (63.4%, $n = 26$). All patients had a Child-Pugh classification of A-B (≤ 7 points) and an ECOG score of 0-1. In the majority of cases (92.7%, $n = 38$), the etiopathology was hepatitis B virus (HBV) infection. The baseline characteristics between the two groups were highly comparable in terms of liver function, demographics, and disease characteristics.

Treatment efficacy

The median follow-up was 21.8 months (95%CI, 14.7-28.8). Patients in the PTL group had significantly longer mPFS (5.4 months; 95%CI, 3.6-7.3) than those in the TL (2.7 months; 95%CI, 1.7-3.6) group (HR 0.25; 95%CI, 0.12-0.52; $P < 0.001$) (Figure 2). However, there was no significant difference in mOS between the PTL (9.0 months; 95%CI, 7.07-10.93) and TL (8.27 months; 95%CI, 7.65-8.89) for groups ($P = 0.108$) (Figure 2). When stratified by ECOG-PS scores, the patients with ECOG score 0 exhibited a longer mPFS than those with ECOG score 1 (Figure 3). However, no statistical difference in PFS was demonstrated between patients with ≤ 3 tumors vs those with > 3 tumors (5.4 months vs. 4.0 months, $P = 0.178$).

The DCR was superior ($P = 0.046$) in the PTL group (88.9%; 1 CR, 2 PR, and 13 SD) than that in the TL (60.9%; 0 CR, 3 PR, and 11 SD) groups (Table 2). However, the difference in the ORR was not significant ($P = 0.752$) between the PTL (16.7%; 1 CR, and 2 PR) and TL (13%; 0 CR and 3 PR) groups. Waterfall analysis revealed a reduction in tumor sizes in 70.7% (29/41) of patients as per the investigator's assessment (Figure 4).

Table 3 presents independent prognostic factors related to mPFS. In univariate analysis, age, gender, cirrhosis, Child-Pugh grade, ECOG performance status, tumor thrombus, bilirubin, prothrombin time, and the intervention method were significantly associated with mPFS ($P < 0.05$). Finally, we found that the PTL regimen (95%CI, 0.12-0.52;

HR=0.25; $P<0.001$), and a lower ECOG score (95%CI, 1.29-6.16; HR=2.82; $P=0.009$) were favorable factors for prolonged PFS.

Safety

Since post-TACE symptoms of transient AEs disappeared in a short time in most patients, these did not affect the subsequent treatment. We did not summarize these transient AEs related to TACE. Thirty-two patients (78.0%) in the two groups experienced treatment-related AEs, including 12 patients (37.5%) with high-grade AEs (\geq grade 3) (**Table 4**). The most frequent treatment-related AEs were asthenia, hand-foot skin reaction, proteinuria, hypertension, decreased white blood cell (WBC) and platelet counts, hypoproteinemia, ascites, nausea, and decreased weight, and most of these AEs were mild to moderate in severity. The incidence of AEs of \geq grade 3 was similar between the two groups. Immune-related AEs included myocarditis (1 patient, grade 2) and hypothyroidism (2 patients, grade 2). The incidence of dose reduction/discontinuation during treatment was 30.4% (7/23) in the TL group and 27.8% (5/18) in the PTL group.

DISCUSSION

HCC patients complicated with PVTT have a short life expectancy. Due to a high susceptibility toward intravascular and extrahepatic metastases, increased risk of other serious complications, including bleeding from esophageal varices, and impaired liver function caused by primary hepatic occlusion and worsening hypertension [27]. The updated recommendations of the National Comprehensive Cancer Network for advanced-stage HCC refer to systemic therapy [28]. In the era of combination drug therapies, TKIs combined with ICIs, such as Lenvatinib combined with Pembrolizumab or Nivolumab, Cabozantinib combined with Nivolumab or Atezolizumab, have been proven to offer higher efficacy and longer OS in HCC patients [29]. The addition of TACE further improves the response of this combination (TKI plus ICI) therapy for advanced-stage HCC subjects [21,22,30]. However, there are no head-to-head studies on the efficacy of TACE or Hepatic artery infusion chemotherapy (HAIC) added with

Lenvatinib/PD-1 inhibitor *vs* TACE plus Lenvatinib in a subset of advanced HCC patients complicated with PVTT. Our study identified an advantage of triplet therapy in terms of mPFS (5.4 months ¹ vs. 2.7 months, $P<0.001$) as well as DCR (88.9% vs. 60.9%, $P=0.046$) in HCCs with PVTT types I-IV. And no new additional toxicities were found. These results were complementary to the previous findings [21,22,30], suggesting the triplet regimen could be utilized in advanced HCC cases, including those with PVTT types I-IV.

The probable mechanism underlying the superiority of the triplet regimen over the dual regimen in treating PVTT in terms of prognosis could be as follows: TACE-induced release of inflammatory factors might have activated the adaptive immunity, or TACE might induce spontaneous T cell responses to regulate the immune environment in the tumor microenvironment. Simultaneously, its combination with ICIs may be more effective in promoting antitumor immune reconstitution [31]. Previous findings have highlighted that tumor immune escape mainly occurs when CTLs are depleted. The immune-promoting activities of anti-VEGF drugs can suppress the expression of PD-1 as well as mucin domain-containing protein 3 (TIM-3) on CTLs, thereby rescuing the CTL population from the depleted state and forming a newly balanced immune environment during treatments [17]. A single-arm investigation has indicated that the PTL regimen could achieve an ORR of 80.6% with manageable toxicity [29].

Although our study demonstrated the superiority of the PTL regimen over the TL, the mPFS was shorter in our study than in the previous study [21]. The following two reasons were considered: first, this study used advanced-stage HCC patients (63.4% with types III-IV PVTT) with poor prognoses as a sample, while the previous study using a triple regimen did not include all patients with PVTT, and second, the small sample size used in this study might have caused some variations in the results. We noticed that the mOS of patients treated with PTL was not statistically different compared to that of TL-treated patients. We speculated that the second-line treatment after progression might have exerted a certain impact on the overall survival of

patients. For example, the combination with PD-1 inhibitors of patients in the dual group after progression further prolonged the survival time of patients. At the same time, for more accurate and reliable results, randomized controlled trials (RCTs) are needed in the future.

Furthermore, we analyzed the prognostic factors of PFS of the whole cohort and concluded that the treatment mode and the ECOG-PS score were independent factors that could modulate the prognosis of HCC patients. When the ECOG-PS score was lower, the mPFS of patients was better. Moreover, the triplet therapy of the PTL regimen could provide better mPFS to patients than the dual therapy with the TL regimen.

Consistently, the PTL regimen has been shown to offer a similar safety profile in this study [21]. The incidences of treatment-related AEs did not differ considerably between the two treatment modalities. Notably, the triplet therapy regimen was not associated with any recurrences of liver injuries, as well as no grade 3 ir-AEs in our study. A recent study has demonstrated that transient transaminase elevation (e.g., 52% in ALT, or 46% in AST) after TACE could be associated with objective responses [32], which can guide clinical practice. It means that patients with severe liver injury may have limited efficacy from TACE, maybe the severe liver injuries induce liver function deterioration which can hinder the administration of systemic drugs. However, due to limited data sources, no such association was investigated in this study.

Some critical limitations of this study are as follows. First, it was a single-center, small-sample, retrospective, and investigator-biased study. Second, the variability in TACE frequency might have affected the results of this study. Third, the cohort size was too small to obtain reliable statistical power for this study. And lastly, the use of different PD-1 blockers could have influenced the consistency of treatment procedures.

CONCLUSION

In conclusion, we found that the triple therapy with PTL could not only significantly improve mPFS and DCR in advanced HCC patients with PVTT but also

prove to be better safety and tolerability. Therefore, based on the previous as well as current findings, it may be concluded that the PTL regimen has powerful potential in obtaining satisfactory treatment outcomes in advanced-stage HCC patients complicated with PVTT types I-IV. Prospective multi-center RCTs are warranted to further confirm the clinical efficacy of the triplet regimen over conventional procedures for HCC with PVTT.

ARTICLE HIGHLIGHTS

Research background

The incidence and mortality of Hepatocellular carcinoma are among the highest in the world. There are a large number of advanced liver cancer patients with portal vein cancer embolus, and the prognosis is worse. Therefore, it is necessary to explore the treatment plan that can prolong the survival of liver cancer patients with portal vein cancer embolus.

Research motivation

To compare the efficacies and safety levels of the PTL regimen and TL regimen for HCC subjects comorbid with PVTT, providing a choice for exploring the combination drug regimen that can prolong the survival of HCC with PVTT.

Research objectives

Our research aims to compare the efficacies and safety levels of the PTL regimen and TL regimen for HCC subjects comorbid with PVTT,. We found a triplet regimen of PTL was safe and well-tolerated as well as exhibited favorable efficacy over the TL regimen for advanced-stage HCC patients with PVTT types I-IV. The triple therapy regimen may better improve the prognosis of advanced liver cancer patients with portal vein cancer suppository and extend their survival time, which is of great significance.

Research methods

We selected HCC patients with PVTT type I-IV, TACE was carried out by 2 professional radiologists

Research results

The triple therapy regimen may better improve the prognosis of advanced liver cancer patients with portal vein cancer suppository and extend their survival time. Large-scale prospective studies are needed to further validate the efficacy and safety of the triple therapy regimen in the future.

Research conclusions

A triplet regimen of PTL was safe and well-tolerated as well as exhibited favorable efficacy over the TL regimen for advanced-stage HCC patients with PVTT types I-IV.

The combination therapy of TACE, TKI and PD-1 inhibitor was used for advanced liver cancer patients with portal vein cancer embolus.

Research perspectives

Large-scale prospective studies are needed to further validate the efficacy and safety of the triple therapy regimen in the future.

ACKNOWLEDGEMENTS

We thank all patients for their endeavors and unparalleled contributions to this study.

6%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.ncbi.nlm.nih.gov Internet	98 words — 3%
2	synapse.koreamed.org Internet	19 words — 1%
3	sjtrem.biomedcentral.com Internet	16 words — < 1%
4	id.nii.ac.jp Internet	14 words — < 1%
5	genomemedicine.biomedcentral.com Internet	13 words — < 1%
6	kclpure.kcl.ac.uk Internet	13 words — < 1%
7	docksci.com Internet	12 words — < 1%
8	sci-hub.se Internet	12 words — < 1%
9	wprim.whooc.org.cn Internet	12 words — < 1%

EXCLUDE QUOTES ON
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES < 12 WORDS
EXCLUDE MATCHES < 12 WORDS